Organovo Logo (2 Color Med-Res-082117).png
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
May 21, 2024 08:05 ET | Organovo, Inc.
Poster presented at DDW2024 demonstrating the potential of the Company’s clinical-stage compound, FXR314, in combination with tofacitinib for treating IBD.
Morphic Demonstrates Novel Real-Time Visualization of Small Molecule α4β7 Inhibition of Gut-Trafficking Cells
May 21, 2024 08:00 ET | Morphic Therapeutic
in vivo video presented at DDW 2024 show small molecule α4β7 inhibition rapidly increases rolling velocity & flux of B cells similar to antibodies
Biora-tm_rgb.jpg
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
May 20, 2024 08:00 ET | Biora Therapeutics, Inc.
Four device performance studies demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions.
Organovo Logo (2 Color Med-Res-082117).png
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
May 14, 2024 11:00 ET | Organovo, Inc.
Organovo will be presenting data on the Company’s lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 08:05 ET | Palisade Bio, Inc.
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to...
Mean Plasma Tofacitinib Concentration
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
April 04, 2024 08:00 ET | Biora Therapeutics, Inc.
All pharmacokinetic endpoints were achieved; all NaviCap™ devices performed as intended; no safety signals observed
ABIVAX_Logo-RGB.png
Abivax reports 2023 financial results and operational update
April 02, 2024 02:30 ET | Abivax
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and...
22157.jpg
Ulcerative Colitis Patient Pool Analysis, Market Size and Market Forecast in APAC Region by 2034
March 25, 2024 19:41 ET | Research and Markets
Dublin, March 25, 2024 (GLOBE NEWSWIRE) -- The "Ulcerative Colitis Patient Pool Analysis, Market Size and Market Forecast APAC - 2034" report has been added to ResearchAndMarkets.com's offering.A...
Gastroenterologists
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
March 22, 2024 10:14 ET | Spherix Global Insights
Exton, Pennsylvania, March 22, 2024 (GLOBE NEWSWIRE) -- The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh...
Biora-tm_rgb.jpg
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
February 26, 2024 08:00 ET | Biora Therapeutics, Inc.
Data from SAD cohort expected to be shared during March corporate update; MAD cohorts to begin dosing in March.